NCT01067287View on ClinicalTrials.gov

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

CT-011

Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses

BIOLOGICAL

Dendritic Cell Fusion Vaccine

One week following each infusion of CT-011

Trial Locations (3)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Unknown

Rambam Medical Center, Haifa

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Rambam Health Care Campus

OTHER

collaborator

Gateway for Cancer Research

OTHER

collaborator

United States Department of Defense

FED

lead

Beth Israel Deaconess Medical Center

OTHER